董孟浩,魏文慧,单本杰,等.HER2阳性乳腺癌治疗中蒽环类药物应用的研究进展[J].肿瘤学杂志,2024,30(1):6-12. |
HER2阳性乳腺癌治疗中蒽环类药物应用的研究进展 |
Research Progress on Anthracycline in the Treatment of HER2 Positive Breast Cancer |
投稿时间:2023-07-03 |
DOI:10.11735/j.issn.1671-170X.2024.01.B003 |
|
|
中文关键词: 乳腺癌 HER2 蒽环 新辅助治疗 辅助治疗 |
英文关键词:breast cancer HER2 anthracycline neoadjuvant therapy adjuvant therapy |
基金项目:安徽省重点研究与开发计划(202104j07020040) |
|
摘要点击次数: 311 |
全文下载次数: 153 |
中文摘要: |
摘 要:蒽环类药物是乳腺癌治疗的基石之一,鉴于蒽环类药物令人担忧的心脏毒性限制以及抗人表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)治疗药物的发展,导致蒽环类药物在HER2阳性乳腺癌新辅助和辅助治疗中的地位受到挑战。全文从HER2阳性乳腺癌新辅助和辅助治疗的临床研究中探讨蒽环类药物的“去留”作一综述。 |
英文摘要: |
Abstract: The application of anthracyclic drugs is one of the cornerstones of breast cancer treatment. However, the status of anthracycline drugs in the new adjuvant and adjuvant treatment of human epidermal growth factor receptor 2(HER2) positive breast cancer is facing a challenge at present, due to its cardiac toxicity and the development of new anti-HER2 drugs. This paper discusses the “fate” of anthracycline drugs in new adjuvant and adjuvant treatment of HER2 positive breast cancer, bases on the recent research evidence and evidence-based medicine. |
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |